SHERWOOD, Ore., Jan. 11, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) announced today that Dr. Paul M. Vanhoutte MD, Ph.D., the internationally respected cardiologist and research scientist, has agreed to serve as Co-chairman of the Company's recently formed Scientific Advisory Board (SAB). Dr. Vanhoutte is currently Chair Professor at the Department of Pharmacology and Pharmacy at the Li Ka Shing Faculty of Medicine, University of Hong Kong, China and is director of that distinguished institution's BioPharmaceutical Development Center. Prior to his move to Asia in 2003, Dr. Vanhoutte was Vice President of Research and Development at the Institut de Recherches Internationales Servier, Courbevoie, France (1992-2002), Director of the Center for Experimental Therapeutics, Department of Medicine, Baylor College of Medicine, Houston, Texas (1989-1995), and Consultant to the Department of Physiology and Biophysics and Department of Cardiovascular Medicine at the Mayo Clinic, Rochester, Minnesota (1981-1989). As Co-chairman of the SAB, Dr. Vanhoutte will provide valuable input into ENTIA's research and development strategy and product roadmap.
Dr. Marvin S. Hausman MD, ENTIA's Chief Executive Officer, stated, "I am very excited to be sharing the chairmanship of our SAB with a scientist of Dr. Vanhoutte's stature, who shares our vision of the important role of nutrigenomics in human health." Nutrigenomics is the study of the effects of foods and food constituents on gene expression with resultant personalized nutrition and the potential control of chronic debilitating diseases. "Paul's experience in the development of novel therapeutics, his international contacts, and his expertise in vascular disease and endothelial cell function and regulation will be a great addition to our scientific discussions and implementation planning."
"I have known Dr. Hausman for nearly five years and am very impressed with what I see at Entia Biosciences," said Dr. Vanhoutte. "The discoveries and research being done with Ergothioneine and Ergocalciferol could revolutionize treatments for a wide variety of conditions that have challenged the pharmaceutical industry for decades. Dr. Hausman has assembled a very strong Scientific Advisory Board and I am honored to serve as its Co-Chairman."
About the Scientific Advisory Board
Formed in late 2011, the 10 member Scientific Advisory Board is comprised of experts from industry and academia who are thought leaders in fields critical to ENTIA's success in the marketplace. Joining Drs. Hausman and Vanhoutte will be:
Krishna Bhat Ph.D, MD - Department of Neuroscience & Cell Biology - University of Texas. (Neurodegenerative disease science), Catherine Cahill Ph.D. - Dept. of Pediatrics Biologist, Massachusetts General Hospital. (Gene regulation & signal transduction), Dirk Grundemann Ph.D. - Dept. of Pharmacology - University of Cologne. (Ergothioneine science & transporter), Penny Kris-Etherton Ph.D, R.D. - Distinguished Professor of Nutrition, Penn State University; Editor of the Journal of the American Dietetic Association, American Journal of Clinical Nutrition; and International Journal of Sports Nutrition (Cardiovascular health), Debomoy Lahiri Ph.D. - Professor of Neuroscience, Departments of Psychiatry and of Medical & Molecular Genetics, Indiana University School of Medicine; Editor of the Current Alzheimer's Research Journal. (Anti-aging, Alzheimer's disease and Neurogenetics), Hector Rodriguez MD, Ph.D. - Nephrology/Internal Medicine; Medical Director, DaVita. (Anemia, Kidney disease & Diabetes), Jack Rogers Ph.D. - Associate Professor of Psychiatry & Neuroscience, Harvard Medical School; Director of Neurochemistry Laboratory, Massachusetts General Hospital (Alzheimer's and Parkinson's disease, Down's syndrome), and Jack Vanden Heuvel Ph.D. – Professor of Molecular Toxicology, Penn State University; Founder and CSO of Indigo Biosciences. (Nutrigenomics, nuclear receptors and intercellular transcription factors)
About Entia Biosciences, Inc.
ENTIA is an emerging leader in food science biotechnology that identifies, scientifically validates, and commercializes solutions that address multi-billion dollar markets for organic health, beauty and agriculture. Formerly named Total Nutraceutical Solutions, the Company's growing portfolio of intellectual property includes extraction, enhancement, and uses for some of the most powerful antioxidants and bio-nutrients occurring in nature.
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences (ENTIA) and/or Total Nutraceutical Solutions (TNS), Inc. with the Securities and Exchange Commission. Further information on risks faced by ENTIA and TNS are detailed in the Form 10-K for the year ended December 31, 2010 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. ENTIA and TNS does not undertake any obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
For more information, please visit our web sites at www.entiabio.com and www.totalnutraceutical.com.